William BSc - AngioSoma Dev Director
| GSTC Stock | USD 0.0003 0.00 0.00% |
Insider
William BSc is Dev Director of AngioSoma
| Age | 68 |
| Phone | 206 451 1970 |
| Web | https://www.globestarthera.com |
AngioSoma Management Efficiency
The company has return on total asset (ROA) of (44.2826) % which means that it has lost $44.2826 on every $100 spent on assets. This is way below average. AngioSoma's management efficiency ratios could be used to measure how well AngioSoma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 9 records | INSIDER Age | ||
| Raul Pascual | Copa Holdings SA | N/A | |
| Robert Neal | Allegiant Travel | 39 | |
| Sonya Wolford | SkyWest | N/A | |
| Peter Donkersloot | Copa Holdings SA | 36 | |
| Alain Bellemare | Delta Air Lines | 63 | |
| Julianne Canavaggio | Copa Holdings SA | ||
| Rebecca Aretos | Allegiant Travel | 48 | |
| Robert Rivkin | United Airlines Holdings | 63 | |
| Bill Dykes | SkyWest | N/A | |
Management Performance
| Return On Asset | -44.28 |
AngioSoma Leadership Team
Elected by the shareholders, the AngioSoma's board of directors comprises two types of representatives: AngioSoma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AngioSoma. The board's role is to monitor AngioSoma's management team and ensure that shareholders' interests are well served. AngioSoma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AngioSoma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert CPA, Treasurer CFO | ||
| Brooke Greenwald, Chief Officer | ||
| James Katzaroff, CEO and President | ||
| Steven Penderghast, Commercial Director | ||
| David Croom, Ex VP | ||
| William BSc, Dev Director |
AngioSoma Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is AngioSoma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -44.28 | |||
| Current Valuation | 9.39 M | |||
| Shares Outstanding | 770.36 M | |||
| Shares Owned By Insiders | 10.02 % | |||
| Shares Owned By Institutions | 0.02 % | |||
| Price To Sales | 78,201 X | |||
| Gross Profit | (2.41 K) | |||
| EBITDA | (1.21 M) | |||
| Net Income | (1.49 M) | |||
| Cash And Equivalents | 12 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in AngioSoma Pink Sheet
AngioSoma financial ratios help investors to determine whether AngioSoma Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AngioSoma with respect to the benefits of owning AngioSoma security.